Adam Colborn, JD, associate vice president for congressional affairs at the Academy of Managed Care Pharmacy, discusses how the Trump administration’s “most favored nation” drug-pricing agreements test the limits of executive authority, signal potential long-term shifts in obesity treatment policy, and could drive broader market and regulatory realignments across both public and private payers.Please introduce […]
